Novartis AG
NVSEF
$106.50
-$3.64-3.30%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 3.61B | 2.82B | 3.19B | 3.25B | 2.69B |
| Total Depreciation and Amortization | 1.15B | 165.00M | 1.16B | 1.12B | 1.16B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 894.00M | 1.47B | 1.11B | 563.00M | 753.00M |
| Change in Net Operating Assets | -2.01B | -255.00M | 824.00M | -50.00M | -2.33B |
| Cash from Operations | 3.65B | 4.19B | 6.29B | 4.88B | 2.27B |
| Capital Expenditure | -254.00M | -558.00M | -321.00M | -260.00M | -227.00M |
| Sale of Property, Plant, and Equipment | 10.00M | 47.00M | 1.00M | 37.00M | 1.00M |
| Cash Acquisitions | -- | -426.00M | -58.00M | -3.29B | -241.00M |
| Divestitures | -4.00M | 164.00M | 7.00M | -26.00M | -38.00M |
| Other Investing Activities | 578.00M | -2.26B | -3.00M | 335.00M | -394.00M |
| Cash from Investing | 330.00M | -3.03B | -374.00M | -3.21B | -899.00M |
| Total Debt Issued | 556.00M | -24.00M | 3.67B | 3.04B | 1.22B |
| Total Debt Repaid | -1.08B | -82.00M | -1.16B | -2.21B | -67.00M |
| Issuance of Common Stock | 1.00M | 0.00 | 5.00M | 25.00M | -- |
| Repurchase of Common Stock | -2.72B | -2.76B | -2.85B | -1.62B | -1.10B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -5.33B | 0.00 | -- | -2.42B | -5.21B |
| Other Financing Activities | 23.00M | -128.00M | -43.00M | -25.00M | -11.00M |
| Cash from Financing | -8.55B | -3.00B | -382.00M | -3.20B | -5.16B |
| Foreign Exchange rate Adjustments | 180.00M | -314.00M | 176.00M | -34.00M | -126.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.39B | -2.15B | 5.71B | -1.57B | -3.92B |